Butterfly Network, the American digital health company specialising in handheld ultrasound technology, has submitted a Form 144 filing with the US Securities and Exchange Commission dated 5 June. The form, which typically notifies the market of a planned sale of restricted shares by an insider or major shareholder, does not specify the exact number of shares or price, but such filings often precede a reduction in holdings.
The company, listed on the New York Stock Exchange under the ticker BFLY, has faced a challenging year amid broader tech sell-offs and slower-than-expected adoption of its flagship Butterfly iQ+ device. Shares have traded well below their 2021 highs, and the filing could add downward pressure if the market interprets it as a lack of confidence from insiders.
For UK investors, Butterfly Network is not a FTSE constituent, but it is held by some London-based fund managers and appears in a number of US-focused exchange-traded funds (ETFs) popular with British pension savers. Any significant price movement in BFLY could ripple through these funds, particularly those with a healthcare or medtech tilt.
Analysts at US brokerages have been cautious on the stock, citing ongoing cash burn and competition from larger medical device manufacturers. The Form 144 filing does not guarantee a sale will occur, but it does allow insiders to trade under Rule 144, which governs the sale of restricted securities. Investors should monitor subsequent filings for concrete transaction details.
The broader context for UK shareholders is the persistent volatility in growth and technology stocks, which has been exacerbated by higher interest rates in both the US and UK. While Butterfly Network's innovative product pipeline remains intact, the company has yet to achieve sustained profitability, making it a higher-risk holding for retail investors and pension funds alike.